Synagistics Limited — Board/Management Information 2023

May 31, 2023

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [63 x 86] intentionally omitted <==

WEALTHKING INVESTMENTS LIMITED 華 科 資 本 有 限 公 司

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1140)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND CO-CHAIRMAN

The board (‘‘Board’’) of directors (‘‘Directors’’) of Wealthking Investments Limited (the ‘‘Company’’) is pleased to announces that effective 31 May 2023, Dr. Wang Qin (‘‘Dr. Wang’’) is appointed as a non-executive Director and the co-chairman (‘‘Co-Chairman’’) of the Board.

Dr. Wang, aged 57, has over 30 years’ experience in finance, investment and fund management. The major appointments of Dr. Wang include working at the Securities Department of Hainan Hong Kong and Macao International Trust Company Limited (海 南 港 澳 國 際信 託 有限 公司 ) from 1991 to 1993; serving as the deputy general manager of Sanya Oriental Industrial Company Limited (三亞東方 實 業股份有限 公司 ) from 1993 to 1995; and serving as the head of the Research Department of Guosen Securities Co., Ltd. from 1997 to 2001. From 2017 to 2020, Dr. Wang served as the general manager of ChiNext Qianhai Capital Co., Ltd. Dr. Wang has substantial fund management experience including working as the deputy general manager for Great Wall Fund Management Co., Limited from 2002 to 2009; as the general manager for Baoying Fund Management Co., Ltd. from 2010 to 2016; and as the general manager for Changan Fund Management Co., Ltd. from 2021 to April 2023.

Dr. Wang obtained a Bachelor’s degree in Economics from Zhengzhou University in 1987; a Master’s degree in Finance from the Graduate School of the People’s Bank of China in 1991; a PhD degree in Economics from the Graduate School of the People’s Bank of China in 1997; and an EMBA degree from the PBC School of Finance (PBCSF), Tsinghua University in 2018.

– 1 –

As a non-executive Director, Dr. Wang will not hold any management or executive role in the Company other than holding the office of non-executive Director and attending Board meetings. As the Co-Chairman of the Board, Dr. Wang will be mainly responsible for the strategic planning of the Company. Given Dr. Wang’s extensive experience in finance, investment and fund management, the Board is confident that he will contribute enormous insight in the future development of the Company.

Dr. Wang will hold the office of non-executive Director until the forthcoming annual general meeting, and will be subject to retirement and re-election in accordance with the Rules Governing the Listing of Securities on the Stock Exchange (the ‘‘Listing Rules’’) and the articles of association of the Company. Dr. Wang has entered into a service contract with the Company pursuant to which Dr. Wang is entitled to a director’s fee of HK$500,000 per annum. Dr. Wang’s remuneration was determined by the Board with reference of his duties and responsibilities within the Company, the prevailing market conditions of companies of comparable size and similar operations, and will be subject to review by the remuneration committee of the Board from time to time.

Other than as stated above, Dr. Wang (i) is not related to any Director, senior management or substantial shareholder or controlling shareholder of the Company; (ii) does not hold any other positions in the Company or its subsidiaries; and (iii) does not hold any directorship in the last three years in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

As at the date of this announcement and within the meaning of Part XV of the SFO, Dr. Wang does not have any interests in the shares of the Company.

Other than the above, there are no other matters in relation to the appointment of Dr. Wang as a non-executive Director that need to be brought to the attention of the shareholders of the Company, nor is there any information that should be disclosed pursuant to any of the requirements of Rule 13.51 (2) of the Listing Rules.

By order of the Board Wealthking Investments Limited Liu Zhiwei Executive Director and Chairman

Hong Kong SAR, 31 May 2023

As at the date of this announcement, the Board comprises one executive Director, namely, Dr. Liu Zhiwei; three non-executive Directors, namely Dr. Wang Qin, Dr. Fu Weigang and Dr. Wang Shibin; and three independent non-executive Directors, namely, Mr. Chen Yuming, Mr. Yan Xiaotian and Mr. Zhao Kai.

– 2 –